Uncategorized
Phase 2 study begins for noninfectious uveitis candidate filgotinib
A phase 2 study of filgotinib, a noninfectious uveitis candidate from Galapagos NV, has begun, according to a company press release.The trial, led by collaboration partner Gilead Sciences, will evaluate the safety and efficacy of filgotinib vs. placebo administered for 52 weeks in 110 adult patients with active noninfectious uveitis.